Tirzepatide vs Semaglutide: Which GLP-1 Is Right for You?

The quick answer

Tirzepatide produces more weight loss than semaglutide on average. The clinical data is clear on this: approximately 22.5% body weight loss with tirzepatide's highest dose versus approximately 14.9% with semaglutide's highest dose. But both medications work. Both are safe. And the one that is "right" for you depends on your metabolic profile, your budget, your insurance coverage, and your physician's clinical judgment.

This is not a simple "one is better" comparison. Semaglutide has a longer track record, more published cardiovascular data, a lower compounded price point, and an oral formulation already on the market. Tirzepatide has stronger weight loss data, a dual mechanism that may offer broader metabolic benefits, and is the newer, more potent option. This guide covers every dimension of the comparison so you and your physician can make the right call.

How they work: GLP-1 only vs dual GLP-1 and GIP

The fundamental difference between tirzepatide and semaglutide comes down to how many hormonal pathways each medication activates. This is not a marketing distinction — it directly explains the difference in clinical outcomes.

Semaglutide: single GLP-1 agonist

Semaglutide activates GLP-1 (glucagon-like peptide-1) receptors exclusively. GLP-1 is an incretin hormone your body produces naturally after eating. When semaglutide activates these receptors, it stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying so you feel full longer, and acts on appetite centers in the hypothalamus to reduce hunger and food cravings. The brand names are Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management). Both are manufactured by Novo Nordisk.

Tirzepatide: dual GLP-1 and GIP agonist

Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. It does everything semaglutide does through GLP-1, plus it adds the GIP pathway. GIP activation enhances insulin sensitivity, promotes fat oxidation, and appears to have additive effects on appetite suppression when combined with GLP-1 signaling. This dual mechanism is widely believed to explain why tirzepatide produces greater weight loss and more substantial metabolic improvements in clinical trials. The brand names are Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Both are manufactured by Eli Lilly.

The analogy is straightforward: semaglutide pushes one lever, tirzepatide pushes two. The clinical data confirms that two levers produce a bigger effect on average. But individual biology is complex, and some patients respond better to the single-mechanism approach. For a broader comparison of the branded medications, see our Ozempic vs Mounjaro guide.

Clinical trial data: STEP vs SURMOUNT

The most rigorous comparison comes from the Phase 3 clinical trial programs for each medication. While these were separate trials (not a direct head-to-head in the weight loss indication), they enrolled similar patient populations and used comparable endpoints.

The data clearly favors tirzepatide for average weight loss. The 15 mg dose produces roughly 50% more weight loss than semaglutide 2.4 mg, and nearly double the proportion of patients achieve 20% or greater body weight reduction. Discontinuation rates due to adverse events were similar, suggesting comparable tolerability.

For diabetes specifically, the SURPASS-2 trial directly compared tirzepatide to semaglutide in patients with type 2 diabetes. Tirzepatide produced superior A1c reductions at all doses tested and greater weight loss as a secondary endpoint. This is the only head-to-head trial between the two molecules.

Side effects: head-to-head comparison

Both medications share the same primary side effect profile because they both activate GLP-1 receptors. The gastrointestinal effects drive most patient complaints and are the main reason slow dose titration is critical for both.

Interestingly, tirzepatide shows lower rates of most gastrointestinal side effects despite producing more weight loss. This may be related to the GIP component, which has been suggested to have a protective effect against nausea. However, these numbers come from different trials with different reporting methodologies, so direct comparison should be interpreted cautiously. Both medications are generally well tolerated when titrated slowly.

Both carry rare but serious risks including pancreatitis, gallbladder disease, and a boxed warning about medullary thyroid carcinoma risk based on animal studies. These risks are not meaningfully different between the two medications. For detailed information on managing GLP-1 side effects, see our semaglutide side effects guide.

Cost comparison: branded vs compounded

For the majority of patients paying out of pocket, cost is often the deciding factor. The pricing landscape differs significantly between branded and compounded options.

At branded prices, the difference is negligible. At compounded prices, semaglutide is typically $50 to $100 per month cheaper than tirzepatide, making it the more budget-friendly option for patients using compounding pharmacies. Insurance coverage for weight loss indications remains inconsistent for both medications, though diabetes indications have better coverage. For a complete breakdown of how to access GLP-1s at the lowest cost, see our cheapest GLP-1 guide.

Dosing schedules compared

Both are administered as once-weekly subcutaneous injections. The titration schedules differ in starting dose, step increments, and maximum dose.

Both medications reach their target dose in approximately 16 to 20 weeks. Tirzepatide has an additional titration step (12.5 mg before reaching 15 mg), which extends its full titration by about four weeks. In practice, many patients achieve their weight loss goals at lower doses and never titrate to the maximum. Your physician will adjust the titration speed based on your response and tolerance.

Which one is right for you: a decision framework

Your physician should ultimately make this recommendation based on your labs, medical history, and goals. But here is the framework that typically guides the decision.

Tirzepatide may be the better fit if: You want the strongest available weight loss results. You have significant insulin resistance or type 2 diabetes alongside obesity. You have tried semaglutide and plateaued or had an inadequate response. You are comfortable with the slightly higher compounded cost. You want the dual GLP-1 and GIP mechanism for broader metabolic benefits.

Semaglutide may be the better fit if: Cost is a primary concern and compounded semaglutide fits your budget better. You want a medication with a longer real-world track record and more published cardiovascular safety data from the SELECT trial. You prefer the option with an oral formulation already available (Rybelsus). You are using the medication primarily for diabetes management and value the cardiovascular outcome data. Your insurance covers Ozempic or Wegovy but not Mounjaro or Zepbound.

The most important factor is neither of these. It is having a qualified physician managing your protocol, monitoring your labs, and adjusting your treatment based on your individual response. Whether you start with tirzepatide or semaglutide, the fundamentals of safe, effective weight management are the same. To explore your options, see our complete weight loss medications guide, learn about getting Mounjaro online, or compare Ozempic vs Mounjaro by brand name.

Frequently asked questions

Which causes more weight loss, tirzepatide or semaglutide?

Tirzepatide produces more weight loss on average. In clinical trials, tirzepatide 15 mg produced 22.5% body weight loss at 72 weeks versus 14.9% with semaglutide 2.4 mg at 68 weeks. However, individual results vary and some patients respond better to semaglutide.

What is the difference between tirzepatide and semaglutide?

Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors, a dual mechanism that produces greater metabolic effects. Both are once-weekly injectable medications used for weight loss and type 2 diabetes management.

Is tirzepatide safer than semaglutide?

Both have similar safety profiles. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. Discontinuation rates due to adverse events are comparable in clinical trials. Neither has been shown to be meaningfully safer than the other.

Can I switch from semaglutide to tirzepatide?

Yes, switching under physician guidance is safe and common. Your physician will start you at a low tirzepatide dose when your next semaglutide dose would have been due. No washout period is needed.

Which is cheaper, tirzepatide or semaglutide?

At branded prices, they are comparable. At compounded prices, semaglutide is typically $50 to $100 per month cheaper. For the lowest prices, see our cheapest GLP-1 guide.

Do both work for type 2 diabetes?

Yes. Ozempic (semaglutide) and Mounjaro (tirzepatide) are both FDA-approved for type 2 diabetes. In the SURPASS-2 head-to-head trial, tirzepatide produced greater A1c reductions than semaglutide at all doses tested. However, semaglutide has more cardiovascular outcome data from the SELECT trial.